Advancements May Result in Ability to Treat a
Broader Patient Population with Immune Disorders
PHOENIX, May 22, 2023
/PRNewswire/ -- Creative Medical Technology Holdings, Inc.
("Creative Medical Technology" or the "Company") (NASDAQ:
CELZ), a biotechnology company focused on a regenerative
approach to immunotherapy, endocrinology, urology, gynecology, and
orthopedics, today announced significant advances in the ongoing
development of its ImmCelz® (CELZ-100) platform, the
Company's cell-free system which has previously been validated to
supercharge a patient's own cells to treat a number of immune
disorders.
These advances support the Company's prior work in this area and
confirm that the use of fewer donor cells can lower production
costs while producing a more potent and efficacious final
product.
In particular, independent studies confirmed:
- That the ImmCelz® (CELZ-100) platform required 75%
fewer donor patient cells compared to industry standard;
- That the purity of the final ImmCelz® (CELZ-100)
product was greater than 95% compared to the industry standard of
greater than 80%;
- That ImmCelz® (CELZ-100) demonstrated a greater than
200% reduction in functional suppression of effector T cells, which
are a critical concern for patients with autoimmune issues, while
still possessing a high number of functional T regulatory cells;
and
- The ability to verify repeated potency of the final
ImmCelz®(CELZ-100) product.
All experiments were independently conducted and validated on
selected human donor patient cells for accuracy and
reproducibility.
"We are thrilled to have achieved these important milestones in
the development of our ImmCelz® (CELZ-100) platform,
particularly the purity and functionality of the cells while
substantially reducing the production costs," said Timothy Warbington, CEO of Creative Medical
Technology Holdings. "We continue to be optimistic in the
development of the ImmCelz® (CELZ-100)
platform."
"We believe that our ability to reduce the number of donor
patient cells by 75% to obtain a better product for patients is a
potential game changer in immunotherapy," said Courtney Bartlett, DNP – Director of Clinical
Operations. "We now will be able to reach a greater number of
potentially sicker patients who previously may not have been
eligible for an immunotherapy due to the increased risk of donating
a large number of cells. This may potentially allow the Company to
offer and treat even a wider variety of immune patient disorders
that require multiple dosing strategies while maintaining patient
safety."
About ImmCelz®
ImmCelz®, which
is protected by trade secrets and published U.S. patents, utilizes
adult stem cells derived from qualified donors to endow specific
properties to the patient's own immune cells. After the patient's
harvested cells are incubated with the Company's cell-free
reprogramming "cocktail", the cells are re-injected back into the
patient. These "supercharged" cells subsequently "educate" other
cells of the immune system to stop attacking the body, while
preserving the ability to attack foreign pathogens thus providing
immune optimization.
The Company plans to advance multiple indications for
ImmCelz® including Type I diabetes, heart disease, liver
disease, and kidney disease.
About Creative Medical Technology Holdings
Creative
Medical Technology Holdings, Inc. is a biotechnology company
dedicated to the advancement of identifying and translating novel
biological therapeutics in the fields of immunotherapy,
endocrinology, urology, gynecology, and orthopedics and is traded
on NASDAQ under the ticker symbol CELZ. For further information
about the Company, please
visit www.creativemedicaltechnology.com.
Forward Looking Statements
This news release may
contain forward-looking statements including but not limited to
comments regarding the timing and content of upcoming clinical
trials and laboratory results, marketing efforts, funding, etc.
Forward-looking statements address future events and conditions
and, therefore, involve inherent risks and uncertainties. Actual
results may differ materially from those currently anticipated in
such statements. See the periodic and other reports filed by
Creative Medical Technology Holdings, Inc. with the Securities and
Exchange Commission and available on the Commission's website at
www.sec.gov.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-announces-next-milestone-achievements-in-immcelz-platform-development-301830389.html
SOURCE Creative Medical Technology Holdings, Inc.